NCT01417442

BRAF V600E Mutations In Papillary Thyroid Carcinoma

Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Bezmialem Vakif University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Detailed description

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.

Conditions

• Papillary Thyroid Carcinoma

Interventions

Type	Name	Description
GENETIC	BRAF V600E POSITIVITY	BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.

Timeline

• Start date: 2011-07-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2011-08-16
• Last updated: 2011-08-16

Locations

1 site across 1 country: Turkey (Türkiye)